Responses
Health economics
Original research
Cost-effectiveness analysis of penpulimab combined with paclitaxel and carboplatin as a first-line treatment for metastatic squamous non-small cell lung cancer in China
Compose a Response to This Article
Other responses
No responses have been published for this article.